These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38090653)

  • 1. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.
    Jiang A; Pang Q; Gan X; Wang A; Wu Z; Liu B; Luo P; Qu L; Wang L
    Cancer Innov; 2022 Aug; 1(2):146-167. PubMed ID: 38090653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.
    Jiang A; Luo P; Chen M; Fang Y; Liu B; Wu Z; Qu L; Wang A; Wang L; Cai C
    Cell Biosci; 2022 Dec; 12(1):209. PubMed ID: 36581992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of AKI signatures and classification patterns in ccRCC based on machine learning.
    Wang L; Peng F; Li ZH; Deng YF; Ruan MN; Mao ZG; Li L
    Front Med (Lausanne); 2023; 10():1195678. PubMed ID: 37293297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma.
    Jiang A; Meng J; Bao Y; Wang A; Gong W; Gan X; Wang J; Bao Y; Wu Z; Lu J; Liu B; Wang L
    Front Oncol; 2021; 11():755212. PubMed ID: 34804944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options.
    Liu Z; Xu H; Weng S; Ren Y; Han X
    Front Immunol; 2022; 13():828330. PubMed ID: 35154148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
    Meng J; Jiang A; Lu X; Gu D; Ge Q; Bai S; Zhou Y; Zhou J; Hao Z; Yan F; Wang L; Wang H; Du J; Liang C
    Imeta; 2023 Nov; 2(4):e147. PubMed ID: 38868222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
    Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
    Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response.
    Su Y; Zhang T; Lu J; Qian L; Fei Y; Zhang L; Fan S; Zhou J; Tang J; Chen H; Liang C
    Cells; 2023 Jan; 12(1):. PubMed ID: 36611973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
    Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
    Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.
    Chen X; Tu J; Ma L; Huang Y; Yang C; Yuan X
    Int J Gen Med; 2022; 15():3215-3235. PubMed ID: 35342303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
    Zhou Z; Yang Z; Cui Y; Lu S; Huang Y; Che X; Yang L; Zhang Y
    Front Genet; 2022; 13():787884. PubMed ID: 35350243
    [No Abstract]   [Full Text] [Related]  

  • 18. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
    Bao W; Han Q; Guan X; Wang Z; Gu M
    Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
    Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
    Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.